Antiviral prophylaxis and treatment (excluding HIV therapy)

Journal of Clinical Virology

Volumn 25, Issue 3, 2002, Pages 241-266

  Waugh, S M L ^a   Pillay, D ^b   Carrington, D ^c   Carman, W F ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c Public Health Laboratory   (United Kingdom)

Author keywords

Antiviral drugs; Clinical management; Viral illness

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; LAMIVUDINE; OSELTAMIVIR; PEGINTERFERON ALPHA; PENCICLOVIR; RIBAVIRIN; RIMANTIDINE; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; ZANAMIVIR;

ADENOVIRUS; AGITATION; ALOPECIA; ANEMIA; ANTIMICROBIAL THERAPY; ANXIETY DISORDER; ARENAVIRUS; ATAXIA; BONE MARROW SUPPRESSION; BRONCHOSPASM; BUNYAVIRUS; CENTRAL NERVOUS SYSTEM; CHICKENPOX; CLINICAL FEATURE; COMA; CYTOMEGALOVIRUS; DISORIENTATION; DYSARTHRIA; ENCEPHALITIS; EPSTEIN BARR VIRUS; GASTROINTESTINAL DISEASE; HALLUCINATION; HEMIPARESIS; HEMOLYTIC ANEMIA; HEPATITIS B; HERPES; HERPES VIRUS; HUMAN; HYPERESTHESIA; HYPOCALCEMIA; IMMUNE DEFICIENCY; INFLUENZA; INFLUENZA VIRUS; INSOMNIA; KIDNEY DISEASE; LETHARGY; LOUDNESS RECRUITMENT; MYOCLONUS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PAPILLOMA VIRUS; PARAINFLUENZA VIRUS; POLYOMA VIRUS; POXVIRUS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEIZURE; THYROID DISEASE; TREMOR; VIRUS INFECTION; VIRUS TYPING;

ANIMALS; ANTIVIRAL AGENTS; CHICKENPOX; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRUS DISEASES;

EID: 0036888137     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00151-8     Document Type: Review

References (153)

1. AGUM and MSSVD. Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Disease. Clinical effectiveness group. National Guideline for the Management of Genital Herpes 2001.
2. Andrews E.B., Yankaskas B.C., Cordero J.F., Schoeffler K., Hampp S. Acyclovir in pregnancy registry: six years experience. Obstet. Gynecol. 79:1992;7-13.
3. Antman K., Chang Y. Medical progress: Kaposi's sarcoma. N. Engl. J. Med. 342:2000;1027-1038.
4. Asano Y., Yoshikawa T., Suga S., Kobayashi I., Nakashimi T., Yazaki T., et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics. 92:1993;219-222.
5. Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Disease. Clinical effectiveness group. National Guideline for the Management of Anogenital Warts 2001.
6. Bacigalupo A., Bregante S., Tedone E., Isaza A., Van Lint M.T., Trespi G., et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation. 62:1996;376-380.
7. Bethge W., Beck R., Jahn G., Mundinger P., Kanz L., Einsele H. Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation. Bone Marrow Transplant. 24:1999;1245-1248.
8. Bethune C.A., Gompels M.M., Taylor C., Angus B., Spickett G.P. Treatment of EBV driven lymphoprolipheration with erythrophagocytosis: 12 year follow up. J. Clin. Pathol. 54:2001;328-331.
9. Beutner K.R. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. 28:1995;281-290.
10. Beutner K.R., Friedman D.J., Forszpaniak C., Anderson P.L., Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39:1995;1546-1553.
11. Blanche S., Tardieu M., Rustin P., Slama A., Barret B., Firtion G., et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 354:1999;1084-1089.
12. Booth J.C.L., Foster G.R., Kumar U., Galassini R., Golden R.D., Brown J.L., et al. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut. 36:1995;427-432.
13. Booth J.C.L., O'Grady J., Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 49:(Suppl 1):2001;1-21.
14. Bordigoni P., Carret A.S., Venard V., Witz F., Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 32:2001;1290-1297.
15. Boulter E.A., Thornton B., Bauer D.J., Bye A. Successful treatment of experimental B virus (herpesvirus simiae) infection with aciclovir. Br. Med. J. 280:1980;681-683.
16. Braig S., Luton D., Sibony O., Edlinger C., Boissinot C., Blot P., et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Euro. J. Obstet. Gynecol. 96:2001;55-58.
17. Breman J.G., Henderson D.A. Current concepts: diagnosis and management of smallpox. N. Engl. J. Med. 346:2002;1300-1308.
18. Breuer J. Vaccination to prevent varicella and shingles. J. Clin. Path. 54:2001;743-747.
19. British HIV Association (BHIVA). Guidelines for the Treatment of HIV Infected Adults with Antiretroviral Therapy 2001.
20. British National Formulary (43), March 2002.
21. Cameron C.E., Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependant RNA polymerase. Curr. Opin. Infect. Dis. 14:2001;757-764.
22. Cohen J. Blocking smallpox: a second defense. In: vaccines for biodefense: a system in distress. Science. 294:2001;500.
23. Conti D.J., Freed B.M., Singh T.P., Gallichio M., Gruber S.A., Lempe N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch. Surg. 130:1995;1217-1221.
24. Cook R.C., Connors J.M., Gascoyne R.D., Fradet G., Levy R.D. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet. 354:1999;1698-1699.
25. Couch R.B. Drug therapy: prevention and treatment of influenza. N. Eng. J. Med. 343:2000;1778-1787.
26. Dancey D.R., Chamberlain D.W., Krajden M., Palefsky J., Alberti P.W., Downey G.P. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir. Case report and review of the literature. Chest. 118:2000;1210-1214.
27. Davies E.G., Thrasher A., Lacey K., Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet. 353:1999;2042.
28. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 323:1986;464-467.
29. Degreef H. Famciclovir herpes zoster clinical study group. Famciclovir, a new oral antiherpes drug. Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int. J. Antimicrob. Agents. 4:1994;241-246.
30. Dellemijn P.L., Brandenburg A., Niesters H.G., van den Bent M.J., Rothbarth P.H., Vlasveld L.T. Successful treatment with ganciclovir of presumed Epstein-Barr meningo-encephalitis following bone marrow transplant. Bone Marrow Transplant. 16:1995;311-312.
31. De luca A., Giancola M.L., Amassari A., Grisetti S., Cingolani A., Larussa D., et al. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J. Neurovirol. 7:2001;364-3687.
32. Department of Health. Immunisation against infectious disease, 1996.
33. Di Bisceglie A.M. Combination therapy for hepatitis B. Gut. 50:2002;443-445.
34. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W.L., Goodman Z., et al. For the US Lamivudine Investigator Group. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Eng. J. Med. 341:1999;1256-1263.
35. Diggory P., Fernandez C., Humphrey A., Jones V., Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver Zanamavir: randomized controlled trial. BMJ. 322:2001;577-579.
36. Dolin R., Reichman R.C., Madore H.P., Maynard R., Linton P.N., Webber-Jones J. A controlled trial of amantidine and rimantidine in the prophylaxis of influenza A infection. N. Engl. J. Med. 307:1982;580-584.
37. Drake S., Taylor S., Brown D., Pillay D. Improving the care of patients with genital herpes. BMJ. 321:2000;619-623.
38. Drew W.L. Ganciclovir resistance: a matter of time and titre. Lancet. 356:2000;609-610.
39. Dunkle L.M., Arvin A.M., Whitley R.J., Rotbart H.A., Feder H.M., Feldman S., et al. A controlled trial of acyclovir for chickenpox in normal children. N. Engl. J. Med. 325:1991;1539-1544.
40. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler U., Jahn G., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:1995;2815-2820.
41. Elizaga J., Olavarria E., Apperley J.F., Goldman J.M., Ward K.N. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin. Infect. Dis. 32:2001;413-418.
42. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Virol. 11:2001;83-86.
43. Englund J.A., Piedra P.A., Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am. J. Med. 102:1997;61-70.
44. Enria D.A., Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 23:1994;23-31.
45. Ernst M.E., Franey R.J. Acyclovir-and ganciclovir-induced neurotoxicity. Ann. Pharmacother. 32:1998;111-113.
46. Faqi A.S., Klug A., Merker H.J., Chahoud I. Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum. Exp. Toxicol. 16:1997;505-511.
47. Field H.J. Herpes simplex virus antiviral drug resistance - current trends and future prospects. J. Clin. Virol. 21:2001;261-269.
48. Field H.J., Darby G. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob. Agents Chemother. 17:1980;209-216.
49. Fisher-Hoch S.P., Khan J.A., Rehman S., Mirza S., Khurshid M., McCormick J.B. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet. 346:1995;472-475.
50. Fried M.W., Shiffman M.L., Reddy R.K., et al. Pegylated (40 kDa) interferon alpha 2a in combination with ribavirin: efficacy and safety results from a phase 3, randomized, actively-controlled multicenter study. Gastroenterology. 120:2001;A567.
51. Gane E., Saliba F., Valdecacas G.J.C., O'Grady J., Pescovitz M.D., Lyman S., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet. 350:1997;1729-1733.
52. Gasnault J., Kousignian P., Kahraman M., Rahoiljaon J., Matheron S., Delfraissy J.F., et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J. Neurovirol. 7:2001;375-381.
53. Geerinck K., Lukito G., Snoeck R., De Vos R., De Clercq E., Vanrenterghem Y., et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:2001;543-549.
54. Gonzales-Fraile M.I., Canizo C., Caballero D., Hernandez R., Vazquez L., Lopez C., et al. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transplant. Infect. Dis. 3:2001;44-46.
55. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meye J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118:1993;173-178.
56. Gruhn B., Meerbach A., Egerer R., Mentzel H.J., Hafer R., Ringelmann F., et al. Successful treatment of Epstein-Barr virus-induced transverse myelitis with ganciclovir and cytomegalovirus hyperimmune globulin following unrelated bone marrow transplantation. Bone Marrow Transplant. 24:1999;1355-1358.
57. Grundy J.E., Shanley J.D., Griffiths P.D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet. 2:1987;996-999.
58. Gubareva L.V., Kaiser L., Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet. 355:2000;827-835.
59. Gubareva L.V., Kaiser L., Matrosovich M.H.N., Soo-Hoo Y., Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with Oseltamivir. J. Infect. Dis. 183:2001;523.
60. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1998;1257-1262.
61. Hall C.B. Medical progress: respiratory syncytial virus and parainfluenza virus. N. Eng. J. Med. 344:2001;1917-1928.
62. Hammond J., Koontz D.L., Bazmi H.Z., Beadle J.R., Hostetler S.E., Kini G.D., et al. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob. Agents Chemother. 45:2001;1621-1628.
63. Haque T., Crawford D. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Br. J. Haematol. 106:1999;309-316.
64. Hart G.D., Paya C.V. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Virol. 11:2001;73-81.
65. Hayden F.G., Atmar R.L., Schilling M., Johnson C., Poretz D., Paar D., The Oseltamivir study group, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 341:1999;1336-1343.
66. Hayden F.G., Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantidine. Curr. Top. Microbiol. Immunol. 176:1992;119-130.
67. Hohenthal U., Nikoskelainen J., Vainionpaa R., Peltonen R., Routamaa M., Itala M., et al. Parainfluenza virus type 3 infections in a hematology unit. Bone Marrow Transplant. 27:2001;295-300.
68. Holmes G.P., Chapman L.E., Strewart J.A., Straus S.E., Hilliard J.K., Davenport D.S. Guidelines for the prevention and treatment of B-virus infections in exposed persons. The B virus working group. Clin. Infect. Dis. 20:1995;421-439.
69. Hopwood P., Crawford H.C. The role of EBV in post-transplant malignancies: a review. J. Clin. Pathol. 53:2000;248-254.
70. Houston S., Roberts N., Mashinter L. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. Clin. Infect. Dis. 32:2001;150-152.
71. Huff J.C., Bean B., Balfour H.H., Laskin O.L., Connor J.D., Corey L., et al. Therapy of herpes zoster with oral acyclovir. Am. J. Med. 85:1988;84-89.
72. Huggins J.W., Hsaing C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., et al. Prospective double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy for hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1991;1119-1127.
73. Johnston R.E., Geretti A., Prentice H.G., Clark A.D., Wheeler A.C., Potter M., et al. HHV-6-related secondary graft failure following allogeneic bone marrow transplantation. Br. J. Haematol. 105:1999;1041-1043.
74. Jouan M., Katlama C. Management of CMV retinitis in the era of highly active antiretroviral therapy. Int. J. Antimicrobial Agents. 13:1999;1-7.
75. Kedes D.H., Ganem D. Sensitivity of kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J. Clin. Invest. 99:1997;2082-2086.
76. Kimberlin DW, Lin CY, Sanchez P, Demmler G, Dankner W, Shelton M, Edwards K, Jacobs RF, Robinson J, Wright J, Lakeman FD, Kiell JM, Soong SJ, Whitely RJ. Ganciclovir treatment of symptomatic congenital cytomegalovirus infections: results of phase III clinical trial. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000, 274.
77. Kimpen J.L.L. Management of respiratory syncytial virus infection. Curr. Opin. Infect. Dis. 14:2001;323-328.
78. Lai C.L., Chien R.N., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:1998;61-68.
79. La Rosa A.M., Champlin R.E., Mirza N., Gajewski J., Giralt S., Rolston K.V., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin. Infect. Dis. 32:2001;871-876.
80. Legrand F., Berrebi D., Houhou N., Freymuth F., Faye A., Duval M., et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 27:2001;621-626.
81. Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 356:2000;645-649.
82. Lindsay K.L., Trepo C., Heintges T., Schiffman M.L., Gordon S.C., Hoefs J.C., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 34:2001;3950-4030.
83. Linn W.S., Gong H., Anderson K.R., Clark K.W., Shamoo D.A. Exposures of health-care workers to ribavirin aerosol: a pharmacokinetic study. Arch. Environ. Health. 50:1995;445-451.
84. Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs. 61:2001;187-196.
85. Ljungman P., de la Camara R., Milpied N., Volin L., Russell C.A., Crisp A., Valacyclovir international bone marrow transplant study group, et al. Randomised study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 99:2002;3050-3056.
86. Ljungman P., Engelhard D., Link H., Biron P., Brandt L., Brunet S., et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immunoglobulin: experience of European bone marrow transplant group. Clin. Infect. Dis. 14:1992;831-835.
87. Malik A.H., Lee W.M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Int. Med. 132:2000;723-731.
88. Manion D.J., Vibhagool A., Chou T.C., Kaplan J., Caliendo A., Hirs M.S. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Antivir. Ther. 1:1996;237-245.
89. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 358:2001;958-965.
90. Martin D.F., Sierra-Madero J., Walmsley S., Wolitz R.A., Macey K., Georgiou P., et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. 346:2002;1119-1126.
91. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., et al. Lassa fever. Effective therapy with ribavirin. N. Eng. J. Med. 314:1986;20-26.
92. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C. N. Eng. J. Med. 339:1998;1485-1492.
93. Medveczky M.M., Horvath E., Lund T., Medveczky P.G. In vitro antiviral drug sensitivity of the kaposi's sarcoma-associated herpesvirus. AIDS. 11:1997;1327-1332.
94. Mer M., Richards G.A. Corticosteroids in life-threatening varicella pneumonia. Chest. 114:1998;426-431.
95. Milipied N., Vasseur B., Parquet N., Garnier J.L., Antoine C., Quartier P., et al. Humanised anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann. Oncol. 11:(Suppl 1):2000;113-116.
96. Monto A.S., Robinson D.P., Herlocher M.L., Hinson J.M., Elliott M.J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 282:1999;75-77.
97. Mookerjee B.P., Vogelsang G. Human herpesvirus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant. 20:1997;905-906.
98. Morgan-Capner P., Crawcroft N.S. On behalf of the PHLS joint working party of the advisory committees on virology and vaccines and immunization. Commun. Dis. Public Health. 5:2002;59-71.
99. Myalonakis E., Kellas W.M., Fishman J.A. Combination antiviral therapy for ganciclovir resistant cytomegalovirus infection in solid-organ transplant recipients. Clin. Infect. Dis. 34:2002;1337-1341.
100. Nathwani D., Maclean A., Conway S., Carrington D. Varicella infections in pregnancy and the newborn. A review prepared for the UK advisory group on chickenpox on behalf of the British Society for the Study of Infection. J. Infect. 36:(Suppl 1):1998;59-71.
101. Nettleton P.F., Gilray J.A., Reid H.W., Mercer A.A. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 48:2000;205-208.
102. Neyts J., De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob. Agents Chemother. 41:1997;2754-2756.
103. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, responses to antiviral therapy, and effect on transplant outcome. Blood. 98:2001;573-578.
104. Nicholson K.G., Aoki F.Y., Osterhaus A.D.M.E., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of Oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet. 355:2000;1845-1850.
105. Ogilvie M. Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK advisory group on chickenpox on behalf of the British Society for the Study of Infection. J. Infect. 36:(Suppl 1):1998;31-38.
106. Perrillo R., Schiff E., Yoshida E., Statler A., Hirsch K., Wright T., et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 32:2000;129-134.
107. Perry C.M., Balfour J.A. Fomivirsen. Drugs. 57:1999;375-380.
108. Pescovitz M.D., Rabkin J., Merion R.M., Paya C.V., Pirsch J., Freeman R.B., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrobial Agents Chem. 44:2000;2811-2815.
109. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., Stephen E.L. Prophylaxis of rift valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 6:1986;285-297.
110. Pillay D., Emery V.C., Mutimer D., Ogilvie M.M., Carman W., Mutto K., et al. Guidelines for laboratory monitoring of treatment of persistent virus infections. J. Clin. Virol. 25:2002;73-92.
111. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
112. Prentice H.G., Gluckman E., Powles R.L., Ljungman P., Milpied N.J., Camara R., et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European acyclovir for CMV prophylaxis study group. Bone Marrow Transplant. 19:1997;129-133.
113. Prentice H.G., Gluckman E., Powles R.L., Ljungman P., Milpied N., Fernandez Ranada J.M., et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European acyclovir for CMV prophylaxis study group. Lancet. 343:1994;749-753.
114. Randolph A.G., Wang E.E.L. Ribavirin for respiratory syncytial virus lower respiratory tract infection: a systematic overview. Arch. Paediatr. Adolesc. Med. 150:1996;942-947.
115. RCOG. Royal College of Obstetricians and Gynaecologiats. Management of genital herpes in pregnancy. Clinical Green Top Guidelines No 30 2001. Available from www.rcog.org.uk.
116. RCOG. Royal College of Obstetricians and Gynaecologiats. Chickenpox in pregnancy. Clinical Green Top Guidelines No.13 2001. Available from www.rcog.org.uk.
117. Resnick L., Herbst J.S., Ablashi D.V., Atherton S., Frank B., Rosen L., et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA. 259:1988;384-388.
118. Reymen D., Naesens L., Balzarini J., Holy A., Dvorakova H., De Clercq E. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res. 28:1995;343-357.
119. Ribaud P., Scieux C., Freymuth, Morinet F., Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin. Infect. Dis. 28:1999;690-691.
120. Rotbart H.A., Webster A.D. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin. Infect. Dis. 32:2001;228-235.
121. Safrin S., Cherrington J., Jaffe H.S. Clinical uses of cidofovir. Rev. Med. Virol. 7:1997;145-156.
122. Safrin S., Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob. Agents Chemother. 37:1993;2241-2243.
123. Salmaggi A., Maccagnano E., Castagna A., Zeni S., Fantini F., Cinque P., et al. Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosis and progressive multifocal leukoencephalopathy. Neurol. Sci. 22:2001;17-20.
124. Sarisky R.T., Quail M.R., Clark P.E., Nguyen T.T., Halsey W.S., Wittrock R.J., et al. Characterisation of herpes simplex viruses selected in culture for resistance to penciclovir or aciclovir. J. Virol. 75:2001;1761-1769.
125. Scott L.L. Prevention of perinatal herpes: prophylactic antiviral therapy? Clin. Obstet. Gynecol. 42:1999;134-148.
126. Scott L.L., Sanchez P.J., Jackson G.L., Zeray F., Wendel G.D. Acyclovir suppression to prevent cesarian delivery after first-episode genital herpes. Obstet. Gynecol. 87:1996;69-73.
127. Segarra-Newnham M. Vodolo KM. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann. Pharmacother. 35:2001;741-744.
128. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:2001;71-76.
129. Snell N.J. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2:2001;1317-1324.
130. Snoeck R., Bossens M., Parent D., Dalaere B., Degreef H., Van Ranst M., et al. Phase 2 double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33:2001;597-602.
131. Spruance S.L., Crumpacker C.S. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit. Am. J. Med. 73:1982;315-319.
132. Spruance S.L., Rea T.L., Thoming C., Tucker R., Saltzman R., Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomised, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA. 277:1997;1374-1379.
133. Tarlow M.J., Walters S.S. Chickenpox in childhood. A review prepared for the UK advisory group on chickenpox on behalf of the British Society for the Study of Infection. J. Infect. 36:(Suppl 1):1998;39-47.
134. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin Hawley S., et al. Hepatology. 29:1999;889-896.
135. The Impact-RSV study group. Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Paediatrics 1998; 102: 531-537.
136. The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B infections. Lancet 1998; 352: 1877-1881.
137. The PREVENT study group. Reduction of respiratory syncytial virus hospitalisation among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Paediatrics 1997; 99: 93-99.
138. Tynell E., Aurelius E., Brandell A., Julander I., Wood M., Yao Q., et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J. Infect. Dis. 174:1996;324-331.
139. Tyring S.K. Advances in the treatment of herpesvirus infection: the role of famciclovir. Clin. Ther. 20:1998;661-670.
140. Tyring S., Barbarash R.A., Nahlik J.E., Cunningham A., Marley J., Heng M., et al. Collaborative famciclovir herpes zoster study group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123:1995;89-96.
141. US Pharmacopeia Drug Information 1996.
142. van der Horst C., Joncas J., Ahronheim G., Gustafson N., Stein G., Gurwith M., et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J. Infect. Dis. 164:1991;788-792.
143. Van Laar J.A., Buysse C.M., Vossen A.C., Hjalmarsson B., van Den Berg B., van Lom K., et al. Epstein-Barr viral load assessment in immunocompetent patients with fulminant infectious mononucleosis. Arch. Intern. Med. 162:2002;837-839.
144. Van Voris L.P., Betts R.F., Hayden F.G., Christmas W.A., Douglas R.G. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 245:1981;1128-1131.
145. Wagstaff A.J., Bryson H.M. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 48:1994;199-226.
146. Webster D. The potential use of anti-enteroviral drugs in the immunocompromised. Curr. Opin. Infect. Dis. 13:2000;625-629.
147. Wilkins E.G.L., Leen C.L.S., McKendrick M.W., Carrington D. Management of chickenpox in the adult. A review prepared for the UK advisory group on chickenpox on behalf of the British Society for the Study of Infection. J. Infect. 36:(1):1998;49-58.
148. Winston D.J., Ho W.G., Bartoni K., Du Mond C., Ebeling D.F., Buhl W.C., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. 118:1993;179-184.
149. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect if alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann. Int. Med. 119:1993;312-323.
150. Yoshida M., Yamada M., Tsukazaki T., Chatterjee S., Lakeman F.D., Nii S., et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res. 40:1998;73-84.
151. Yuen M.F., Lai C.L. Treatment of chronic hepatitis B. Lancet Infect. Dis. 1:2001;232-241.
152. Zabawski E.J., Cockerell C.J. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J. Am. Acad. Dermatol. 39:1998;741-745.
153. Zwartouw H.T., Humphreys C.R., Collins P. Oral chemotherapy of fatal B virus (herpesvirus simiae) infection. Antiviral Res. 11:1989;275-283.